India to Malaysia: Cisplatin Export Trade Route

The India to Malaysia Cisplatin corridor is one of India's established pharmaceutical export routes, with 16 shipments documented worth a combined $397.7K USD. The route is dominated by VENUS REMEDIES LIMITED, which alone accounts for roughly 52% of all export value, reflecting the consolidated nature of India's cisplatin manufacturing sector.

Across 5 active suppliers, the average shipment value stands at $24.9K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (67%) and air (17%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during April–June, with an average transit time of 25 days port-to-port. The route has recorded an annual growth rate of 23.6%, placing it at rank #5 among India's top cisplatin export destinations globally.

On the import side, key buyers of Indian cisplatin in Malaysia include FRESENIUS KABI MALAYSIA SDN BHD, U S B, UNIMED SDN BHD and 4 others. FRESENIUS KABI MALAYSIA SDN BHD is the single largest importer with 6 shipments valued at $124.3K USD.

India's cisplatin exports to Malaysia are driven primarily by a handful of large-scale manufacturers. VENUS REMEDIES LIMITED with 7 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 5 active exporters signals a competitive but concentrated market — buyers in Malaysia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — VENUS REMEDIES LIMITED, FRESENIUS KABI ONCOLOGY LIMITED, VENUS REMEDIES LIMITED — together account for 90% of total trade value on this route. The average shipment value of $24.9K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as platol 50 mg / 50ml cisplatin concentrate for solution for infusion (50 mg/50 ml) and cisplatin concentrate for sol. for inf.(50 mg/50 ml) (platol) batch no.x4aci044b,mfg. dt. 01/2024, exp. dt.12/2025, suggesting that buyers in Malaysia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, FRESENIUS KABI MALAYSIA SDN BHD is the largest importer with 6 shipments worth $124.3K USD — representing 31% of all cisplatin imports from India on this route. A total of 7 buyers are active on this corridor.